Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Non-Current Assets (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Non-Current Assets for 7 consecutive years, with $212.5 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 5.84% to $212.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $860.0 million through Dec 2025, down 6.66% year-over-year, with the annual reading at $212.5 million for FY2025, 5.84% down from the prior year.
  • Non-Current Assets for Q4 2025 was $212.5 million at Beam Therapeutics, roughly flat from $212.5 million in the prior quarter.
  • The five-year high for Non-Current Assets was $259.1 million in Q2 2023, with the low at $178.7 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $227.1 million, with a median of $225.8 million recorded in 2024.
  • The sharpest move saw Non-Current Assets soared 230.16% in 2021, then fell 10.52% in 2024.
  • Over 5 years, Non-Current Assets stood at $201.4 million in 2021, then increased by 23.52% to $248.8 million in 2022, then fell by 0.06% to $248.7 million in 2023, then dropped by 9.25% to $225.7 million in 2024, then dropped by 5.84% to $212.5 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $212.5 million, $212.5 million, and $215.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.